Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
Do | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit | 191 | ACCESS Newswire | In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire... ► Artikel lesen | |
16.05. | CNS Pharmaceuticals reports Q1 results | 4 | Seeking Alpha | ||
16.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update | 300 | ACCESS Newswire | Cash expected to fund operations into the second half of 2026Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme... ► Artikel lesen | |
15.05. | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
13.05. | CNS Pharmaceuticals Stock Surges 36% On $5 Mln Public Offering Announcement | 1 | RTTNews | ||
13.05. | CNS Pharmaceuticals sets terms for $5 million stock offering | 3 | Investing.com | ||
13.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | 615 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
13.05. | Pre-market Movers: Lobo EV Technologies, CNS Pharmaceuticals, Landsea Homes, Inno Holdings, Lichen International | 468 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.25 A.M. ET).In the Green Lobo EV Technologies Ltd. (LOBO) is up over 160%... ► Artikel lesen | |
13.05. | CNS Pharmaceuticals erhält Orphan-Drug-Status für Krebsmedikament | 7 | Investing.com Deutsch | ||
13.05. | CNS Pharmaceuticals secures orphan drug status for cancer drug | 2 | Investing.com | ||
13.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 | 534 | ACCESS Newswire | Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM)Management... ► Artikel lesen | |
12.05. | CNS Pharmaceuticals, Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
14.04. | CNS Pharmaceuticals files to sell 5.22M shares of common stock, warrants | 1 | Seeking Alpha | ||
14.04. | CNS Pharmaceuticals, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
09.04. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
01.04. | CNS Pharmaceuticals reports FY results | 2 | Seeking Alpha | ||
01.04. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Full Year 2024 Financial Results | 273 | ACCESS Newswire | Company has one year of cash to fund operationsCompany advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy... ► Artikel lesen | |
31.03. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
31.03. | CNS Pharmaceuticals, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
25.03. | XFRA BE5: WIEDERAUFNAHME/RESUMPTION | 290 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CUREVAC | 3,812 | -2,36 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
PALATIN TECHNOLOGIES | 0,088 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
VIVOSIM LABS | 1,570 | -100,00 % | VivoSim Labs, INC. - 10-K, Annual Report | ||
OCUGEN | 0,927 | +11,13 % | Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
BIO-GATE | 1,050 | 0,00 % | Bio-Gate platziert Wandelanleihen im Gesamtwert von 550.000 Euro | Bio-Gate meldet die Platzierung zweier Wandelschuldverschreibungen mit einem Gesamtvolumen von 550.000 Euro. Eine Tranche über 300.000 Euro stammt aus einer am 3. Juni beschlossenen Emission im Gesamtnennbetrag... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,526 | +6,05 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
VAXART | 0,364 | +5,63 % | Vaxart, Inc.: Vaxart Announces Adjournment of Annual Meeting of Stockholders | ||
BURCON NUTRASCIENCE | 0,072 | -1,10 % | Burcon NutraScience Corporation: Burcon to Participate in 2025 Canadian Climate Investor Conference | Vancouver, British Columbia--(Newsfile Corp. - May 28, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 0,330 | -6,25 % | Cellectar +147%: Ich nehme die Gewinne mit! | Meine Spekulation geht auf: Cellectar Biosciences (WKN: A3DQSD) knallt heute in der Spitze um bis zu +147% durch die Decke, nachdem ich im März ein großes Comeback der Aktie in Aussicht gestellt hatte.... ► Artikel lesen | |
AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market | OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ("AIM" or the "Company") (OTC Pink: AIMI) - an immuno-pharma company focused on the research and development of therapeutics to... ► Artikel lesen | |
IMMUNIC | 0,704 | +5,23 % | Immunic sammelt 65 Millionen Dollar ein - Aktie reagiert | Immunic meldet für die erste Tranche einer Kapitalmaßnahme einen Bruttoerlös von rund 65 Millionen Dollar. Das Biotech-Unternehmen platzierte im Rahmen eines öffentlichen Angebots vorfinanzierte Aktien-Warrants... ► Artikel lesen | |
T2 BIOSYSTEMS | 0,106 | +0,95 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen |